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Abstract
Background: Patients scheduled for elective surgery with a high risk of thromboembolism require anticoagulation
bridging therapy perioperatively. The purpose of this study was to assess the risk of thromboembolic events and
bleeding-related complications after total hip and knee arthroplasty in patients requiring bridging therapy for
anticoagulants.
Methods: A retrospective cohort study of all patients with primary total hip or total knee replacement in a 4-year
period was performed. Outcome measures were blood loss, thromboembolic and bleeding-related complications
and hospital stay.
Results: Bridged patients had more blood loss and higher complication rates than the control group. Most
complications were bleeding-related, and there were no thromboembolic events. Seven of the 14 (50 %) total hip
patients bridged with unfractioned heparin required reoperation (three patients with ischial neuropraxia due to
hematoma). There were two bleeding-related deaths in total hip patients bridged with low-molecular-weight
heparin. Mean hospital stay was significantly longer in unfractioned heparin bridging.
Conclusion: In this study, there was a significant increase in bleeding-related complications in total joint
replacement with bridging therapy compared to prophylaxis. This risk was highest in patients with total hip
arthroplasty. There were no thromboembolic events in bridged patients.
Keywords: Anticoagulation, Vitamin K antagonists, Bridging, Heparin, Total hip arthroplasty, Total knee arthroplasty,
Complications, Bleeding
Background
Patients with conditions causing a high risk for thrombo-
embolism (atrial fibrillation, mechanical heart valves or re-
current venous thromboembolism) require long-term oral
anticoagulation (OAC) therapy with vitamin K antago-
nists. Management of anticoagulation forms a challenge
when these patients require elective surgery. Whereas
interruption of OAC increases the risk of thromboembolic
events, continuing results in a risk of bleeding-related
complications. To balance these risks, OAC can be inter-
rupted to obtain normal coagulation during surgery and
restarted as soon as hemostasis is achieved. Based on the
patient’s individual risk for thromboembolism, physicians
determine whether bridging is required [1].
Given the long half-life of vitamin K antagonists, shorter
acting anticoagulation agents such as unfractioned hep-
arin (UFH) or low-molecular-weight heparin (LMWH)
are used as bridging therapy. Traditionally, in-hospital
bridging therapy with intravenously administered UFH
has been used. The advantage is the monitoring ability
with the activated partial thromboplastin time (APTT).
Therapeutic LMWH has the potential benefit that out-
patient treatment is possible. In recent prospective obser-
vational studies, LMWH was shown to be as safe as UFH
in selective procedures with low thromboembolic event
rates of 0.6–3.6 % and major bleeding rates of 0.5–11.3 %
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for both bridging therapies [2–5]. However, there was a
non-significant trend towards an increased bleeding risk
in patients undergoing major procedures in vascular and
general surgery [2, 3]. Although over 40 % of the patients
in these cohorts underwent major surgery, these studies
pooled different procedures by surgical specialty and
lacked control groups. Therefore, extrapolating this data
to assess a patient’s individual complication risk for a spe-
cific procedure is impossible.
Total hip (THA) and total knee arthroplasty (TKA)
are two of the most commonly performed major surgical
procedures in orthopaedic surgery, with a high success
rate. Without predisposing risk factors, the frequency of
venous thromboembolisms after major orthopaedic sur-
gery is high and most guidelines recommend the use of
prophylaxis [6–9]. Despite prophylaxis, a small number
of patients develops venous thromboembolism and re-
quires a therapeutic dose of anticoagulation [7, 10, 11].
Previous studies [12–14] have shown a high incidence
(up to 45 %) of bleeding-related complications and a
considerable morbidity associated with a therapeutic
dose anticoagulation started within 6 days after total
joint arthroplasty (TJA).
The purpose of this study was to assess the risk of
thromboembolic events and bleeding-related complica-
tions in patients undergoing TJA, who require bridging
therapy perioperatively.
Methods
In this retrospective cohort study, all patients receiving a
primary THA or TKA in our tertiary referral centre for
cardiac surgery were included in the years 2008–2012.
The hospital ethics committee approved this study. All
institutional patient records were reviewed by two au-
thors (MH and DK). Medical records were used to ob-
tain patient characteristics, date of surgery, blood loss,
blood transfusion, complications and postoperative hos-
pital stay. The electronic pharmacy database was used to
search for pre- and postoperative anticoagulation ther-
apy. The complication database was checked for compli-
cations within the first 3 months after surgery, and the
Dutch National Orthopaedic Implant Registry (Lande-
lijke Registratie Orthopedische Implantaten, LROI) was
consulted. To minimize the risk of missing thrombo-
embolic events, we matched the codes for THA and
TKA with the codes for lower extremity ultrasound
examination and CT-pulmonary-angiography. All radi-
ology reports were checked.
The indication for bridging therapy was determined by
the anesthesiologist, according to the Dutch National
guidelines. In this guideline, the type of bridging therapy
is not dictated. A multidisciplinary team consisting of
the anesthesiologist, a cardiologist or lung specialist and
the orthopaedic surgeon determined whether UFH or
LMWH was prescribed, and the concerning physician
was involved in the postoperative treatment of the pa-
tient during hospital stay. Dosage was adjusted for pa-
tient’s weight and renal function. Patients requiring
bridging stopped with OAC 3–5 days before surgery. Pa-
tients on intravenous UFH were admitted to the hospital
3 days before surgery to start with treatment. Patients
on LMWH (nadroparin subcutaneously in therapeutic
dose) commenced treatment at home and were admitted
the day before surgery. An international normalized ratio
(INR) ≤1.5 was required for surgery. The target APTT
ratio with UFH treatment was 2–2.5 and was measured
6-hourly. UFH was stopped 6 h before and restarted
12 h after surgery. OAC was restarted when there was
no excessive wound draining. Bridging therapy was
stopped at INR >2.0.
Platelet antiaggregants were stopped 5–10 days before
surgery in all patients. In patients with OAC without in-
dication for bridging, OAC was stopped 3–5 days before
surgery and restarted after surgery when there was no
excessive wound draining. Patients without bridging re-
ceived a daily prophylactic dose nadroparin of 2850
international units (IU) (body weight <90 kg) or 5700 IU
(body weight >90 kg). Prophylactic LMWH was initiated
upon admission the evening before surgery and contin-
ued for 6 weeks postoperatively.
All THAs were performed with a standard posterolat-
eral approach, and a standard medial parapatellar ap-
proach was used for TKAs. All TKAs were cemented. In
all patients, a wound drain with vacuum was placed dur-
ing surgery and removed after 24 h. No tranexamic acid
or cell salvage was used.
The outcome measures were defined as blood loss,
complications and duration of hospital stay. Parameters
for blood loss were haemoglobin (Hb) decrease (preopera-
tive value—lowest Hb level postoperatively) and transfu-
sion requirements. Trigger points for transfusion were Hb
≤4.0 mmol/L in healthy patients (American Society of An-
esthesiologists (ASA) class I), Hb ≤5.0 mmol/L in ASA II/
III and Hb ≤6.0 mmol/L in ASA IV patients. The bleeding
index was calculated (BI = units of packed cells + points
Hb decrease) [15, 16]. The adverse events of interest were
major and minor bleeding, neuropraxia due to hematoma,
reoperation (such as evacuation of hematoma), arterial
thromboembolism including cerebral vascular accidents
(CVA), deep venous thrombosis (DVT), pulmonary em-
bolism (PE), heparin-induced thrombocytopenia, infected
TJA and death. Major bleeding was defined as a bleeding
index >5.0 (more than 3 points of Hb decrease and trans-
fusion with two or more packed cells) or need for opera-
tive evacuation of the haematoma. Minor bleedings were
all other recorded bleeding events which may have re-
sulted in wound healing problems or prolonged hospital
stay. Readmittance within 3 months was also reported.
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Statistical analysis was performed with SPSS software
(version 21, IBM Corporation, Armonk, NY), and differ-
ences were considered significant at p < 0.05. Single factor
analysis of variance (ANOVA) with Bonferroni (for equal
variances) or Tamhane (for unequal variances) post hoc
tests were used to compare the numerical values of the
groups. Fisher’s exact test was used to compare the
categorical variables of the groups.
Results
Of the 2529 patients undergoing a THA or TKA in our
hospital, 35 patients required bridging therapy for OAC.
Indication for bridging therapy was a mechanical heart
valve in 18 (14 aortic, two mitral, two both), biological
heart valve in two, atrial fibrillation (AF) in three
(CHADS2 score 5/6 and/or persistent AF), previous pul-
monary embolism in six, hypercoagulopathy in three (one
patient with Factor-V-Leiden and recurrent DVT and PE
in combination with AF, one patient with hyperhomocys-
teinemia and protein C deficiency with previous DVT and
one patient with hyperhomocysteinemia with recurrent
DVT despite OAC), and an in-stent coronary stenosis in
one patient. In one patient with DVT and PE after previ-
ous contralateral TKA and one patient with postoperative
AF, immediate postoperative therapeutic LMWH was
started. Although these patients did not receive OAC pre-
operatively, they were included in the LMWH bridging
TKA group. Patient characteristics are listed in Table 1.
There were no significant differences in mean age, gender
or type of implant between the different groups. There
was a significant difference in indication for TKA because
of one patient with avascular necrosis in the LMWH
group. Patients with a mechanical heart valve were more
likely to receive UFH as bridging therapy (p < 0.001). As
expected, OAC use was significantly higher and antiaggre-
gants use significantly lower in bridging groups compared
to the prophylaxis group.
The 35 bridging patients had an average body mass
index (BMI) of 27.54 (range 20.4–36.9, one patient un-
known), diabetes was present in seven patients (three
unknown) and the average ASA score was 2.47 (one un-
known). Of the bridged patients, four actively smoked,
four had a past of smoking and three were unknown.
The average operating time including anaesthesia time
of these patients was 87 min.
The patients that were bridged had a significant higher
complication rate and significantly more bleeding-
related complications. For UFH, the OR was 19.8 (95 %
CI 6.50–60.60, p < 0.0001) and 36.8 (95 % CI 14.14–
95.59, p < 0.0001), respectively. For LMWH bridging, the
OR was 6.4 (95 % CI 2.44–16.63, p = 0.0002) and 9.1
(95 % CI 2.89–28.36, p = 0.0002), respectively. Compari-
son between THA and TKA patients did not render stat-
istical significant results.
Total hip arthroplasty
Of the 1517 patients undergoing THA, 23 required
bridging therapy. Table 2 summarizes the outcome mea-
sures after THA. Although there were no major outliers
in APTT, patients bridged with UFH had significantly
higher decreases of haemoglobin levels, number of
transfused units and bleeding index compared to pa-
tients on prophylaxis. There were no significant dif-
ferences in haemoglobin levels, number of transfused
units and bleeding index between the therapeutic and
prophylactic LMWH groups. Mean hospital stay for
patients with UFH was significantly longer (p = 0.009)








(n = 18) (n = 17) (n = 2494)









Osteoarthritis 10 6 1334
Avascular necrosis 1 2 49
Late posttraumatic 2 1 80
Inflammatory arthritis 0 0 14




Osteoarthritis 4 7 975
Avascular necrosis 0 1 2
Late posttraumatic 0 0 7
Inflammatory arthritis 0 0 16
Procedure 0.932
Cemented TKA 4 8 1000
Cemented THA 12 8 1233
Uncemented THA 2 1 151
Hybrid THA 0 0 30




Mechanical heart valve 15 3
Other reason 3 14
Medication of interest <0.001
Anticoagulation 16 13 151
Antiaggregants 0 1a 482
Combined 2 1 8
None 0 2b 1853
aPatient with in-stent coronary stenosis
bOne patient with history of PE and one patient with AF de novo
during operation
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compared to patients on LMWH bridging therapy or
prophylaxis, even after compensation for the 3 days
of preoperative admission.
Bridging patients were significantly more at risk to
have adverse events compared to the prophylaxis group.
Fifteen of the 23 patients (65 %) on bridging therapy had
one or more complications (OR 10.9, 95% CI 5.36–
22.02, p < 0.0001). The complications were bleeding-
related in 10 out of 11 for UFH and three out of four for
LMWH. Bleeding-related complications were signifi-
cantly higher in THA patients with bridging therapy
(odds ratio of 50.9 for UFH and 14.5 for LMWH versus
prophylaxis). Major bleeding occurred in, respectively,
nine (64 %) and three (33 %) of the UFH and LMWH
patients. In eight bridging patients (seven on UFH and
one on LMWH), reoperation with evacuation of the
hematoma was required. In four (three on UFH and one
on LMWH), this was indicated by neuropraxia of the is-
chial nerve which developed in the first postoperative
days. There were no thromboembolic events in patients
on bridging therapy. In the control group, nine patients
(0.6 %) developed a venous thromboembolism (six DVT,
two PE, one both) despite prophylactic LMWH. One
had temporarily stopped OAC which was indicated for
paroxysmal AF. Other patients with thromboembolism
did not use OAC preoperatively. The earliest DVT or
PE in the prophylaxis group occurred 3 days postop-
eratively. No adverse events occurred after initiation
of OAC as treatment for the thromboembolism in
these patients. Four patients in the prophylaxis group
had an arterial thromboembolism. Two patients were
on temporarily stopped antiaggregants and developed
Table 2 Blood loss, length of hospital stay and complications after total hip arthroplasty
UFH bridging LMWH bridging LMWH prophylaxis p value
(n = 14) (n = 9) (n = 1494)
Blood loss
Preop. haemoglobin level, mmol/L (range) 8.0 (6.1–9.4) 8.2 (5.9–9.6) 8.5 (5.3–11.1)a 0.313
Postop. haemoglobin level, mmol/L (range) 5.0 (3.2–6.8) 6.0 (3.7–8.2) 6.5 (3.6–9.0)b <0.001
Haemoglobin decrease, mmol/L (range) 3.0 (0.4–5.3) 2.2 (0.3–5.2) 2.0 (0.3–5.3)c 0.044
Transfusion units Mean (range) 5.8 (0–25) 2.9 (0–18) 0.2 (0–6) 0.040
Median 4 0 0
Bleeding index Mean (range) 8.8 (0.4–30) 5.0 (0.3–22) 2.1 (0.3–9.3)c 0.027
Median 6.9 2.2 1.9
Hospital stay
Mean days (range) 23.9 (7–71) 9.9 (4–27) 6.8 (4–69) 0.009
Median 16 8 6
Complications
Any complication 11 (79 %) 4 (44 %) 218 (14.6 %) <0.001
Bleeding-related complication
Major bleeding 9 (64 %) 3 (33 %) 46 (3.1 %) <0.001
Minor bleeding 0 0 5 (0.3 %) 1.000
Neuropraxia due to hematoma 3 (21 %) 1 (11 %) 0 <0.001
Evacuation of hematoma 7 (50 %) 1 (11 %) 3 (0.2 %) <0.001
Thromboembolic complication
Arterial thromboembolism 0 0 4 (0.3 %) 1.000
Deep venous thrombosis 0 0 7 (0.5 %) 1.000
Pulmonary embolism 0 0 3 (0.2 %) 1.000
Heparin-induced thrombocytopenia 1 (7 %) 0 0 NAd
Infected THA 1 (7 %) 0 13 (0.9 %) 0.194
Death 0 2 (22 %) 4 (0.3 %) 0.001
aTwenty-six values unknown
bFour values unknown
cTwenty-eight values cannot be calculated
dNot applicable, number too small to perform statistics
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a myocardial infarction. OAC or antiaggregants were
also temporarily stopped in two patients with an
ischemic CVA.
Thirteen patients on prophylactic LMWH (0.9 %) had
an early THA infection which was treated with open
debridement, antibiotics and implant retention. Deep
infection developed in none of the LMWH bridging pa-
tients and in one of the UFH bridging patients (7 %). Al-
though the patient on UFH bridging therapy was also
treated with open debridement and antibiotics, the mul-
tiresistant Escherichia coli failed to respond and a tem-
porary Girdlestone was created with vacuum-assisted
wound closure to treat the infection. Eventually, the pa-
tient underwent uncomplicated implantation of THA
with LMWH bridging therapy in a tertiary-care infec-
tious disease and orthopaedic centre. In the first
3 months postoperative, there were two deaths (22 %) in
the LMWH bridging group (massive abdominal bleed-
ing; rectus hematoma with abdominal compartment syn-
drome and acute renal failure) and four deaths (0.3 %) in
the prophylaxis group (sepsis due to early THA infection;
sepsis possibly due to endocarditis; intracerebral haemor-
rhage and herniation syndrome due to undiagnosed brain
tumour; out of hospital death of unknown cause 14 days
postoperatively). None of the UFH patients died in the
first 3 months.
Total knee arthroplasty
Twelve of 1012 patients undergoing TKA required
bridging therapy. Blood loss, complications and hospital
stay are summarized in Table 3. Although there were no
major outliers in APTT, patients on UFH bridging ther-
apy undergoing TKA had a significant higher decrease
of haemoglobin levels and higher bleeding index com-
pared to patients on prophylaxis. There were no signifi-
cant differences in blood loss between the therapeutic
and prophylactic LMWH groups. The mean hospital
stay was not significantly different between the groups.
TKA patients on bridging therapy were more likely to
have adverse events compared to the prophylaxis group.
Eight of the 12 patients (67 %) on bridging therapy had
one or more complications (OR 10.8, 95% CI 3.22–36.37,
p < 0.0001). In two out of five patients bridged with
LMWH and all three patients bridged with UFH, the com-
plications were bleeding-related (OR 93.8 for UFH and
10.4 for LMWH bridging). There were two major and
three minor bleedings in patients on bridging therapy for
which admission was prolonged. No thromboembolic
events occurred in patients on bridging therapy. In the pa-
tients on prophylaxis, nine arterial thromboembolic
events, 13 DVTs and five PEs occurred. The arterial
thromboembolic events consisted of two patients with
myocardial infarction postoperatively after temporarily
stopped antiaggregants, a patient with transient ischaemic
attack and three patients with ischaemic CVA. One on
interrupted antiaggregants and one on interrupted OAC.
The other patient did not receive preoperative OAC or
antiaggregants and died of CVA in the brain stem. In two
patients with temporarily stopped antiaggregants, an em-
bolectomy was required for arterial occlusions at the tri-
furcation of the popliteal artery. These two patients also
had DVT. Of the other patients with DVT, OAC and anti-
aggregants were temporarily stopped in three and two pa-
tients, respectively. None of the patients with pulmonary
embolisms were on preoperative OAC or antiaggregants.
Of the 10 patients (1 %) with an early deep TKA infec-
tion, one (25 %) was on UFH and one (13 %) was on
therapeutic LMWH. All patients with an early infected
TKA were treated with open debridement, antibiotics
and retention of implant. One of the patients on prophy-
laxis developed wound dehiscence after falling, compli-
cated by implant infection and sepsis. This patient had a
history of liver cirrhosis, ascites and congestive heart
failure and died 5 months after TKA of causes related to
complications. Three other prophylaxis patients died in
the first days after TKA (two sudden deaths of unknown
cause; one brain stem CVA).
Discussion
Managing complication risks in patients requiring bridg-
ing therapy during TJA remains a challenge. In this
retrospective study, patients on bridging therapy had a
significantly higher complication risk compared to pa-
tients receiving standard thrombosis prophylaxis. Among
35 patients requiring bridging therapy, 66 % had a compli-
cation in the first 3 months after TJA. The majority of the
complications were bleeding-related, and there were no
thromboembolic events in both bridging groups. Compar-
ing both bridging groups did not render statistically sig-
nificant results for (bleeding-related) complications. There
were differences in odds ratios between the groups, how-
ever. Patients bridged with UFH had the highest risk of
bleeding-related complications in TJA. In TKA patients,
the odds ratio for bridging with UFH was 93.8, compared
to 10.4 for LMWH. In THA patients, this differe nce in
odds ratios was smaller (50.9 for UFH compared to 35.4.
for LMWH). For the THA patients, there were major
consequences like neuropraxia of the ischial nerve or
reoperation. Although no bridging therapy was required
according to the guideline of the American College of
Chest Physicians (ACCP) [7], six of the 151 patients on
interrupted OAC (4 %) received normal prophylactic
LMWH dose and still developed thromboembolic events.
The bleeding-related complication rate of 40 % in this
study is much higher than general reported rates in elect-
ive surgery of 0.9–11.3 % [3–5, 17–23]. However, it ap-
pears not to be incidental as similar high rates are
reported in previous studies of perioperative warfarin
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therapy in TKA and THA [14, 24]. Although patients
without bridging therapy and with therapeutic UFH or
LMWH therapy were pooled in these studies, the overall
rate of excessive wound drainage and superficial or deep
infections were significantly higher in patients on warfarin
therapy compared to a control group. Similar to our re-
sults, the complication rates were highest in a subgroup of
patients on intravenous UFH bridging with 44 and 53 %
of the patients developing excessive wound drainage, 15
and 28 % developing a superficial wound infection and 11
and 19 % developing deep infection after THA and TKA,
respectively. In our study, TKA bridging patients devel-
oped less neuropraxia and required less reoperations com-
pared to THA, possibly due to the fact that the knee is an
encapsulated compartment. The rising of pressure inside
the compartment and the appliance of a pressure bandage
around the knee may aid coagulation.
Considering the high number of bleeding-related com-
plications and low thromboembolic rates in patients on
bridging therapy, it appears that the risks are not well
balanced. Although no thromboembolic events occurred
in patients on bridging therapy, the mortality and mor-
bidity of these complications is significant. This might
explain a tendency to over-coagulate these patients. For
patients with mechanical heart valves on oral anticoagu-
lation therapy, the incidence of valve thrombosis is 0.5
to 6 % per patient-year for aorta and mitralis positions,
respectively [25–27]. For patients with a history of DVT
or pulmonary embolism, the long-term complication risk
is also significant. After 3 months of treatment with
oral anticoagulation, the incidence of recurrent thrombo-
embolism can be as high as 30 % within 8 years [28].
Twenty percent of these recurrent thromboembolic events
were pulmonary embolisms, which were fatal in more
Table 3 Blood loss, length of hospital stay and complications after total knee arthroplasty
UFH bridging LMWH bridging LMWH prophylaxis p value
(n = 4) (n = 8) (n = 1000)
Blood loss
Preop. haemoglobin level, mmol/L (range) 8.5 (8.0–9.2) 8.6 (7.6–10.3) 8.5 (6.2–10.9)a 0.902
Postop. haemoglobin level, mmol/L (range) 5.6 (4.9–6.0) 6.4 (5.0–9.0) 6.5 (4.0–9.9)b 0.104
Haemoglobin decrease, mmol/L (range) 3.0 (2.1–3.9) 2.2 (1.3–4.2) 2.0 (0.2–4.8)c 0.012
Transfusion units n (range) 0.5 (0–2) 0 (0) 0.15 (0–9) 0.449
Median 0.0 0.0 0.0
Bleeding index Mean (range) 3.5 (2.1–5.9) 2.2 (1.3–4.2) 2.1 (0.2–12.4)c 0.045
Median 2.9 1.9 2.0
Hospital stay
Mean days (range) 32.5 (12–83) 9.6 (5–20) 7.4 (4–112) 0.552
Median 17.5 8.5 7
Complications
Any complication 3 (75 %) 5 (63 %) 156 (15.6 %) <0.001
Bleeding-related complication
Major bleeding 1 (25 %) 1 (13 %) 26 (2.6 %) 0.041
Minor bleeding 2 (50 %) 1 (13 %) 5 (0.5 %) <0.001
Neuropraxia due to hematoma 0 0 0 NAd
Evacuation of hematoma 0 0 1 (0.1 %) NAd
Thromboembolic complication
Arterial thromboembolism 0 0 9 (0.9 %) 1.000
Deep venous thrombosis 0 0 13 (1.3 %) 1.000
Pulmonary embolism 0 0 5 (0.5 %) 1.000
Heparin-induced thrombocytopenia 0 0 0 NAd
Infected TKA 1 (25 %) 1 (13 %) 8 (0.8 %) 0.006
Death 0 0 4 (0.4 %) 1.000
aTwenty-two values unknown
bThree values unknown
cTwenty-five values cannot be calculated
dNot applicable, number too small to perform statistics
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than 50 % of the cases. In addition to the higher risk of
recurrent events, these patients also have considerable risk
of developing a postthrombotic syndrome or chronic
thromboembolic pulmonary hypertension.
There is also a tendency of over-treating low-risk
patients, as a recent study reported a poor adherence to
guidelines [29]. In this study, 84.3 % of the patients
received LMWH bridging despite a low thromboembolic
risk profile and had high major bleeding rates. In our
bridging groups, all patients had a high thromboembolic
risk; therefore, the indication for bridging according to
ACCP guidelines was correct and no over-treated
patients were detected.
Just as thromboembolism, increased anticoagulated
state may also cause significant morbidity and mortality.
Obviously, the increased mortality rate due to bleeding-
related complications of two out of 35 patients on bridg-
ing therapy (5.7 %) compared to seven out of 2494 con-
trol patients (0.3 %) is striking. The higher rate of deep
infections and neuropraxia of the ischial nerve causes
long-term impairment. In this study, the majority of the
complications were excessive wound drainage and local
major bleedings which do not have detrimental effects
on long-term morbidity.
Timing of initiation of the postoperative bridging
has been suggested as a critical factor for complica-
tions [13, 14, 24]. In 112 patients requiring thera-
peutic anticoagulation for thromboembolic events in
the early postoperative phase, the complication rate
was 45 % when UFH started within 6 days after TJA
and dropped to 15 % when UFH was started more
than 6 days postoperatively [13]. However, a smaller
study with 29 patients was not able to show differ-
ences in bleeding-related complications when thera-
peutic dosage of anticoagulation was started in the
first 2 days postoperatively or later [14]. A 6-day time
frame is not clinically relevant for patients on bridg-
ing therapy, since therapy needs to be restarted on
the day of surgery. Despite the risks of early initiation
of the bridging therapy, our overall complication rate
was similar to the previous reported rates of starting
anticoagulation within 6 days postoperatively [13, 14].
Two severe complications were the two deaths in the
LMWH bridging group. Both patients died of bleeding-
related complications. These complications were not
directly related to joint replacement surgery, but to
spontaneous bleeding elsewhere. One patient, a 73-year-
old woman with an ASA score of 2, developed a big
abdominal rectus muscle haematoma with an abdom-
inal compartment syndrome. The lowest recorded post-
operative Hb was 4.1 mmol/L, and in total, there was a
required transfusion of 18 packed cells. The patient was
admitted to the ICU and developed acute renal failure.
Further treatment was ceased based on her own and
direct family’s wishes. The family did not give permis-
sion for section of the body. The other patient was an
82-year-old woman with an ASA score of 3. The day
after surgery, the Hb was 5.2 mmol/L, were after, two
packed cells were administered. The patient collapsed
on the ward days after surgery and resuscitation was un-
successful. Section of the body showed approximately
1 L of old blood in the small intestine. These two deaths
probably are the result of spontaneous bleeding due to
anticoagulation. This emphasizes the serious risk of
bridging therapy. Although both patients were bridged
with LMWH, the data shows the risks with UFH are just
as high, if not higher.
Although the data of this study is retrospective, the
search of multiple sources was comprehensive. In con-
trast to the matched control groups in previous studies,
all patients receiving a TJA were included in this study
[14, 24]. Despite the large control group, one of the limi-
tations is the small group size of bridging patients. Com-
paring both bridging groups did not render significant
results. Given the nature of this retrospective study,
there is also the risk of selection bias for type of bridg-
ing. Based on this data, it is difficult to recommend one
of the two bridging protocols. Given the higher odds ratios
for any complication and bleeding-related complications
with UFH bridging, the advantage of outpatient treatment
with LMWH and thus shorter hospital admittance, we
now opt for LMWH bridging in our department.
Conclusions
In conclusion, in this study, bridging oral anticoagulants
with UFH or LMWH during total joint replacement was
safe from a thromboembolic perspective. However, there
was a significant increase in bleeding-related complica-
tions with bridging therapy, with serious consequences
for the patients. This risk was the highest in patients
with total hip arthroplasty. The risks of bleeding-related
and thromboembolic complications have to be carefully
balanced. The high bleeding-related complication rate in
patients on bridging therapy warrants counselling of pa-
tients preoperatively and careful monitoring postopera-
tively. This data also highlights the need for future
studies, including randomized trials, to compare the
safety of UFH and LMWH bridging therapy in patients
undergoing TJA.
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